Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V; Mitotarget study group. Lenglet T, et al. Among authors: ludolph a. Eur J Neurol. 2014 Mar;21(3):529-36. doi: 10.1111/ene.12344. Epub 2014 Jan 21. Eur J Neurol. 2014. PMID: 24447620 Clinical Trial.
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; BENEFIT-ALS Study Group. Shefner JM, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-435. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26982815 Clinical Trial.
Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis.
Wischnewski S, Thäwel T, Ikenaga C, Kocharyan A, Lerma-Martin C, Zulji A, Rausch HW, Brenner D, Thomas L, Kutza M, Wick B, Trobisch T, Preusse C, Haeussler M, Leipe J, Ludolph A, Rosenbohm A, Hoke A, Platten M, Weishaupt JH, Sommer CJ, Stenzel W, Lloyd TE, Schirmer L. Wischnewski S, et al. Among authors: ludolph a. Nat Aging. 2024 Jun 4. doi: 10.1038/s43587-024-00645-9. Online ahead of print. Nat Aging. 2024. PMID: 38834884
Serum heat shock protein concentrations are not associated with amyotrophic lateral sclerosis risk or survival in three European populations.
Rooney JPK, Geoghegan G, O'Reilly F, Heverin M, Bose-O'Reilly S, Casale F, Chio A, Günther K, Schuster J, Klopstock T, Ludolph A, Hardiman O, Rakete S. Rooney JPK, et al. Among authors: ludolph a. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Jun 3:1-9. doi: 10.1080/21678421.2024.2358805. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38826044
Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1.
Olde Heuvel F, Li Z, Riedel D, Halbgebauer S, Oeckl P, Mayer B, Gotzman N, Shultz S, Semple B, Tumani H, Ludolph AC, Boeckers TM, Morganti-Kossmann C, Otto M, Roselli F. Olde Heuvel F, et al. Among authors: ludolph ac. J Neurol Neurosurg Psychiatry. 2024 Jun 2:jnnp-2024-333413. doi: 10.1136/jnnp-2024-333413. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38825349 Free article.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Among authors: ludolph ac. Lancet Neurol. 2024 May 20:S1474-4422(24)00134-0. doi: 10.1016/S1474-4422(24)00134-0. Online ahead of print. Lancet Neurol. 2024. PMID: 38782015
1,030 results